Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease
- PMID: 1900403
- DOI: 10.7326/0003-4819-114-7-563
Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease
Abstract
Objective: To evaluate the effect of a nasal spray preparation of desmopressin (DDAVP) on levels of factor VIII activity, ristocetin cofactor activity, and von Willebrand antigen as well as the length of bleeding time in patients with mild hemophilia A and von Willebrand disease; to determine whether effective hemostatic levels can be attained; and to compare the effect of this spray with that of standard intravenous desmopressin treatment.
Design: Before-and-after trial in patients known to respond to intravenous desmopressin.
Setting: Regional, comprehensive, hemophilia diagnosis and treatment center.
Patients: A total of 22 patients, including 11 patients with von Willebrand disease, 8 patients with mild hemophilia A, and 3 symptomatic hemophilia carriers.
Interventions: Patients were infused with desmopressin, 0.3 micrograms/kg body weight. At least 1 week later, they were taught to self-administer desmopressin nasal spray, 150 micrograms to each nostril.
Measurements: In patients with hemophilia, the level of factor VIII activity was measured; in patients with von Willebrand disease, levels of factor VIII activity, ristocetin cofactor activity, and von Willebrand antigen as well as bleeding time were measured before and after each administration of desmopressin.
Main results: Desmopressin, when administered intravenously or intranasally, elevated levels of factor VIII, ristocetin cofactor, and von Willebrand antigen in both mildly hemophiliac patients and patients with von Willebrand disease when compared with baseline measures (P less than 0.05). Factor VIII levels adequate for hemostasis were achieved by 82% of the hemophiliac patients. An abnormal bleeding time was corrected in the majority (62%) of patients with von Willebrand disease.
Conclusion: A nasal spray preparation of desmopressin apparently was effective both in treating bleeding episodes and when used prophylactically for minor surgical procedures in several patients.
Similar articles
-
Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I.Blut. 1990 Mar;60(3):187-91. doi: 10.1007/BF01720274. Blut. 1990. PMID: 2107887
-
DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.J Pediatr. 1983 Feb;102(2):228-33. doi: 10.1016/s0022-3476(83)80526-5. J Pediatr. 1983. PMID: 6401806
-
Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willebrand disease.J Pediatr. 2002 May;140(5):595-9. doi: 10.1067/mpd.2002.123626. J Pediatr. 2002. PMID: 12032528 Clinical Trial.
-
Desmopressin (DDAVP) for treatment of disorders of hemostasis.Prog Hemost Thromb. 1986;8:19-45. Prog Hemost Thromb. 1986. PMID: 3104987 Review.
-
Desmopressin: a nontransfusional treatment of hemophilia and von Willebrand disease.Haemostasis. 1992;22(5):276-80. doi: 10.1159/000216335. Haemostasis. 1992. PMID: 1478539 Review.
Cited by
-
Desmopressin as a hemostatic and blood sparing agent in bleeding disorders.Eur J Haematol. 2023 May;110(5):470-479. doi: 10.1111/ejh.13930. Epub 2023 Feb 12. Eur J Haematol. 2023. PMID: 36656570 Free PMC article. Review.
-
Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.CMAJ. 1995 Jul 15;153(2):147-57. CMAJ. 1995. PMID: 7600466 Free PMC article.
-
Congenital bleeding disorders. Rational treatment options.Drugs. 1993 Apr;45(4):541-7. doi: 10.2165/00003495-199345040-00006. Drugs. 1993. PMID: 7684674 Review.
-
Acute pulmonary thromboembolism occurring during treatment with tolvaptan in a patient with autosomal-dominant polycystic kidney disease.CEN Case Rep. 2017 May;6(1):61-65. doi: 10.1007/s13730-016-0245-y. Epub 2017 Jan 24. CEN Case Rep. 2017. PMID: 28509130 Free PMC article.
-
Improved oral delivery of desmopressin via a novel vehicle: mucoadhesive submicron emulsion.Pharm Res. 1996 Jul;13(7):1083-7. doi: 10.1023/a:1016023111248. Pharm Res. 1996. PMID: 8842050
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical